Darusentan is a selective endothelin ETA receptor antagonist. It is being evaluated as a treatment for congestive heart failure and hypertension.
For the treatment of congestive heart failure and hypertension.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.